Crude Oil (CL)

Dernières nouvelles pour Colgate-Palmolive (NYSE:CL) Stock

COLGATE-PALMOLIVE CO

Colgate-Palmolive

Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.

Colgate-Palmolive Co

Core One Labs Inc

CHINA LIAONING DINGXU ECO by China Liaoning Dingxu Ecological Agriculture Development, Inc.

China Liaoning Dingxu Ecological Agriculture Development Inc

Clarus Corp

CHAVANT CAPITAL ACQUISITION CORP UNIT 1 COM & 1/3 WT EXP

CLARITAS PHARMACICLS INC by CLARITAS PHARMACEUTICALS INC.

Claritas Pharmaceuticals Inc

Core Laboratories Inc

CALBEE Inc

Columbia Financial Inc

CALIBER ENERGY INC by Caliber Energy, Inc.

Colombier Acquisition Corp. II Class A Ordinary Shares

Colombier Acquisition Corp II

Colombier Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share

Cellebrite DI Ltd

CHRISTINA LAKE CANNABIS by Christina Lake Cannabis Corp.

Christina Lake Cannabis Corp

CLICKS GROUP LTD S/ADR by Clicks Group Ltd

Clicks Group Ltd

CENTRAL CHINA SECS S/ADR by Central China Securities Co. Ltd.

Calcol Inc

Sinch AB

Cool Co Ltd

CEL CORP by CEL CORP.

Cell Source Inc

CapitaLand China Trust

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Direxion Daily Cloud Computing Bull 2X Shares

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging Trust

Chatham Lodging Trust (REIT) 6.625% Series A Cumulative Redeemable Preferred Shares of Beneficial Interest

Cloud3 Ventures Inc Ordinary Shares (Sub Voting)

CLOUD3 VENTURES INC by CLOUD3 VENTURES INC

Cloud3 Ventures Inc

Calidi Biotherapeutics Inc Warrants (01/01/9999)

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

Coles Group Ltd

COLES GROUP LTD UNSP/ADR by Coles Group Ltd.

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education Holdings Ltd

CONCRETE LEVELING SYS INC by Concrete Leveling Systems Inc.

Concrete Leveling Systems Inc

Cleveland-Cliffs Inc

Clearfield Inc

CLIFFORD MDERN IVING HLD by CLIFFORD MODERN LIVING HLDGS LTD.

CLARITY METALS CORP by Clarity Metals Corp.

Clarity Metals Corp

Aris Mining Corp

CLEGHORN MINERALS ORD by Cleghorn Minerals

Cleghorn Minerals Ltd

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies Ltd

CLEANGO INNOVATIONS INC by CleanGo Innovations Inc.

CleanGo Innovations Inc

CLEAN SEED CAP GROUP LTD by Clean Seed Capital Group Ltd

Clean Seed Capital Group Ltd

Cloud Nine Web3 Technologies Inc

HUTECH21 CO LTD NEW by Hutech21 Co., Ltd.

Hutech21 Co Ltd

Clean Harbors Inc

ClearDAO

CLST Holdings Inc

COLTENE HOLDING AG ORD by Coltene Holding AG

Coltene Holding AG

Tidal Trust II Veridien Climate Action ETF

Energy Plug Technologies Corp

CORDLIFE GROUP LTD ORD by Cordlife Group Ltd

Cordlife Group Ltd

CLS HOLDINGS PLC ORD by CLS Holdings Plc.

CLS Holdings PLC

Click Holdings Ltd

CAPITALAND INVESTMENT LTD by Capitaland Investment Ltd.

CapitaLand Investment Ltd

CLEAN EARTH ACQUISITIONS CORP RT

CLEAN EARTH ACQUISITIONS CORP UNIT 1 CL A COM & 1 RT 1/2 RED WT EXP

CLEAN EARTH ACQUISITIONS CORP RED WT EXP

Global X Funds Global X 1-3 Month T-Bill ETF

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies Corp

CLEARFORD WATER SYS INC by Clearford Water Systems, Inc.

Clearford Water Systems Inc

ClickStream Corp

CITY OF LONDON INVST GRP by City of London Investment Group PLC

City of London Investment Group PLC

ProShares Long Online/Short Stores ETF

Clarke Inc

Calcitech Ltd

TWC ENTERPRISES LTD ORD by TWC Enterprises Ltd.

TWC Enterprises Ltd

CLAYTON & LAMBERT MFG CO by Clayton & Lambert Manufacturing Co.

CHALLENGER GOLD LIMITED by Challenger Gold Limited

Challenger Gold Ltd

COLLINS FOODS LTD NWMKT by Collins Foods Ltd Newmarket Qld

Collins Foods Ltd

BICO Group AB

COLLECTIVE METALS INC by COLLECTIVE METALS INC.

Collective Metals Inc

CELLNEX TELECOM UNSP/ADR by Cellnex Telecom SA

Cellnex Telecom SA

Cellectis S.A. - American Depositary Shares

Cellectis SA

CALLINEX MINES INC by Callinex Mines Inc.

Callinex Mines Inc

Cornerstone Strategic Investment Fund, Inc. Common Shares

Cornerstone Strategic Value Fund Inc

Climb Global Solutions, Inc. - Common Stock

Climb Global Solutions Inc

CALIMA ENERGY LTD NEW by Calima Energy Ltd.

Calima Energy Ltd

CALGRO M3 HOLDINGS LTD by Calgro M3 Holdings Ltd.

Calgro M3 Holdings Ltd

Climeon AB ass B

Climeon AB

CANADIAN PREM SAND by Canadian Prem Sand Inc.

Canadian Premium Sand Inc

Calumet Inc

Clean Energy Fuels Corp

CALIAN GROUP LTD ORD by Calian Group Ltd.

Calian Group Ltd

Clene Inc

NYLI Cleaner Transport ETF

CLEAN VISION CORPORATION by Clean Vision Corporation

Clean Vision Corp

CELLNEX TELECOM SA ORD by Cellnex Telecom SA

Callisto - United States Dollar

iShares AAA CLO Active ETF

CloakCoin

Wells Fargo analyst Chris Carey maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Underweight and raises the price target from $83 to $88.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on Colgate-Palmolive, Raises Price Target to $88

WIIM

DLTR

Shares of consumer staples stocks are trading higher as tariffs uncertainty may be driving a shift towards defensive stocks.

Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $98.41, a high estimate of $112.00, and a low estimate of $83.00. Observing a downward trend, the current average is 4.62% lower than the prior average price target of $103.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1743422421_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Colgate-Palmolive by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$83.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$121.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Colgate-Palmolive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Colgate-Palmolive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Colgate-Palmolive's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>Unveiling the Story Behind Colgate-Palmolive</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Understanding the Numbers: Colgate-Palmolive's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Colgate-Palmolive faced challenges, resulting in a decline of approximately -0.1% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 228.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.5%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 40.15, Colgate-Palmolive faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Colgate-Palmolive: 17 Analysts Share Their Views

Piper Sandler analyst Korinne Wolfmeyer maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $108 to $107.

Piper Sandler Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $107

Goldman Sachs analyst Bonnie Herzog analyzed the pet food offerings to understand the category more. The following are the comments published on Thursday regarding the same.
The U.S. consumer is becoming more cautious due to concerns about inflation, tariffs, and geopolitical uncertainty, impacting the broader staples sector, said the analyst.
While consumer packaged goods (CPG) companies face short-term pressure, an analysis of the pet food market suggests that premium offerings from Colgate-Palmolive Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) and General Mills Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) are likely to remain resilient.
These high-end products could support growth and help offset weaker demand in other areas, noted the analyst.
The analyst <a href="https://www.benzinga.com/quote/CL/analyst-ratings">reiterated a Buy rating</a> on the shares of Colgate-Palmolive with a price forecast of $106.00. The Hill&#8217;s Pet Nutrition division is expected to be a key driver of sustained mid-single-digit organic sales growth, fueled by category expansion and market share gains.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44517020/ev-maker-mullen-automotive-to-further-cut-costs-and-slash-workforce" rel="noreferrer noopener">EV Maker Mullen Automotive To Further Cut Costs And Slash Workforce: Details</a>
The global premium pet food market is projected to grow at around 5% through 2030, with balanced contributions from volume and pricing.
While dry dog food growth is expected to moderate, wet dog food is gaining traction. Cat food, both dry and wet, is anticipated to see stronger growth due to increasing consumption.
Despite an overall slowdown in category growth, Colgate is well-positioned to outperform the market, said the analyst.
The company&#8217;s focus on innovation such as Hill&#8217;s Prescription Diet z/d Low Fat and new wet cat food flavors along with above-average advertising spend and expanded production capacity, is set to drive household penetration beyond its current 6% in the U.S.
With solid revenue growth and productivity improvements, Colgate is expected to see continued margin expansion, supporting strong earnings.
The analyst reiterated a <a target="_blank" href="https://www.benzinga.com/quote/GIS/analyst-ratings" rel="noreferrer noopener">Buy rating on General Mills</a> with a price forecast of $68.00. The company sees its pet food business as a key catalyst for returning to 2% &#8211; 3% organic sales growth by fiscal 2027, with fiscal 2026 focused on reinvestment.
Premium pet food, benefiting from the increasing humanization of pets, is expected to drive mid-single-digit category growth, with contributions from both pricing and volume, noted the analyst.
GIS has historically expanded market share through acquisitions, and its recent Whitebridge purchase is expected to follow suit.
With a strong presence in pet specialty and e-commerce but low household penetration, the brand offers a significant growth runway, particularly in the high-growth cat food segment.
Despite competition from private labels, GIS&#8217;s premium positioning has supported sales acceleration and market share stability, opined the analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44497833/exxon-mobil-eyes-semiconductor-boom-with-99-999-pure-isopropyl-alcohol-production-expansion-details" target="_blank" rel="noreferrer noopener">Exxon Mobil Eyes Semiconductor Boom With 99.999% Pure Isopropyl Alcohol Production Expansion: Details</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Reiteration

Trading Ideas

General

Goldman Sees Premium Pet Food As Bright Spot For Colgate And General Mills Amid Consumer Caution

Barclays analyst Lauren Lieberman maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Equal-Weight and raises the price target from $83 to $89.

Barclays Maintains Equal-Weight on Colgate-Palmolive, Raises Price Target to $89

The increase will be effective in the second quarter, 2025. The Board declared that the second quarter dividend is to be paid on May 15, 2025 to shareholders of record as of April 17, 2025.&nbsp;

Dividends

Colgate-Palmolive Increases Quarterly Common Stock Cash Dividend From $0.50 To $0.52 Per Share

This replaces the Company's previous $5 billion share repurchase program authorized in 2022.

Buybacks

Colgate-Palmolive Plans Repurchase Of Shares Of Up To $5B Under New Share Repurchase Program

During the last three months, 15 analysts shared their evaluations of Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Colgate-Palmolive, presenting an average target of $98.47, a high estimate of $112.00, and a low estimate of $83.00. This current average has decreased by 5.5% from the previous average price target of $104.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986049_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Colgate-Palmolive among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$83.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$121.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Colgate-Palmolive. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Colgate-Palmolive's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Colgate-Palmolive's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>All You Need to Know About Colgate-Palmolive</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>A Deep Dive into Colgate-Palmolive's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Colgate-Palmolive's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -0.1%. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Colgate-Palmolive's ROE excels beyond industry benchmarks, reaching 228.44%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Colgate-Palmolive's ROA excels beyond industry benchmarks, reaching 4.5%. This signifies efficient management of assets and strong financial health.
Debt Management: Colgate-Palmolive's debt-to-equity ratio is notably higher than the industry average. With a ratio of 40.15, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 15 Analysts Discuss Colgate-Palmolive Stock

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and raises the price target from $97 to $99.

JP Morgan Maintains Overweight on Colgate-Palmolive, Raises Price Target to $99

Colgate-Palmolive shares are trading lower after the company, speaking at a conference, reportedly said it has noticed hesitancy in the consumer.

Colgate-Palmolive Executiuve Says Co Has Noticed Hesitancy In The Consumer Given All The News Flow; Says There Will Be An Impact Both From Initial Tariffs With Mexico And Canada As Well As Any Sort Of Retaliatory Tariffs

Shares of consumer staples stocks are trading lower. The sector may be down amid a rotation into tech stocks on Wednesday. Investors may also be assessing February CPI data, which showed slowing food inflation.

COTY

Shares of consumer stocks are trading lower. Weak guidance from Kohl's may causing consumer spending concerns. Additional steel and aluminum tariffs may also increase input costs for some companies.

CALM

MDLZ

Shares of consumer staples stocks are trading higher. Strength in the sector may be due to defensive rotation as investors assess tariff uncertainty and recent economic data.

Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) is broadening its footprint in the pet food industry through the purchase of Care TopCo Pty Ltd, the parent company of Prime100, an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43799390/colgate-palmolive-company-announces-agreement-to-acquire-prime100" rel="noreferrer noopener">Australian fresh pet food brand</a>.
Prime100, founded in 2014 and located in Melbourne, Australia, produces both refrigerated and shelf-stable pet food, which is distributed through pet care retailers and other Australian markets.
The acquisition aligns with the company&#8217;s strategy to tap into rapidly growing markets that complement its main business areas and strengthen its position in Australia&#8217;s pet food market.
By acquiring Prime100, Colgate-Palmolive will enhance its Hill&#8217;s Pet Nutrition division, gaining access to the thriving fresh pet food segment while reinforcing its portfolio of science-based, veterinarian-approved products.
&#8220;Prime100 is a strong, veterinarian-endorsed, premium-priced brand with distinctive positioning that fits well within our long-term pet nutrition growth strategy,&#8221; said Colgate Chairman, President and CEO Noel Wallace.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43791589/why-is-uber-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Uber&#8217;s Ski Service Launches Across Europe: Details</a>
&#8220;We are excited that this acquisition will add a high-growth, profitable fresh dog food asset to the Hill&#8217;s division portfolio with the opportunity to drive continued growth through expanded distribution and awareness.&#8221;
The transaction is set to be completed in the second quarter of 2025, pending regulatory approval in Australia. Colgate plans to fund the deal with a combination of debt and cash.
As of December 31, the company held $1.09 billion in cash and <a target="_blank" href="https://www.benzinga.com/25/01/43385529/colgate-palmolive-posts-mixed-q4-gloomy-outlook" rel="noreferrer noopener">equivalents</a>.&nbsp;The acquisition is not expected to significantly affect its diluted earnings per share in 2025.
Price Action: CL shares closed higher by 0.41% at $86.39 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43791187/costco-travel-taps-travelport-tech-to-upgrade-booking-experience" target="_blank" rel="noreferrer noopener">Costco Travel Taps Travelport Tech To Upgrade Booking Experience</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Colgate-Palmolive Expands Into Fresh Pet Food Market With Prime100 Acquisition

Based in Melbourne, Australia, Prime100 is a fresh pet food brand offering both refrigerated and shelf stable products, sold to pet specialty and other retailers in Australia. Launched in 2014, Prime100 is a leading fresh pet food brand in Australia, driven by its science-backed product lines and veterinary endorsement.
The transaction will be financed with a combination of debt and cash and is currently expected to close in the second quarter of 2025. The acquisition is conditioned upon receipt of regulatory approval in Australia.
The transaction is not expected to have a material impact on diluted earnings per share in 2025.
 &nbsp;

Colgate-Palmolive Agrees To Acquire Care TopCo Pty Ltd, Owner Of Prime100 Pet Food Brand; No Terms Disclosed

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $103 to $97.

JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $97

Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) posted mixed results for the fourth <a href="https://www.benzinga.com/quote/CL/earnings">quarter on Friday</a>.
The company reported a fourth-quarter sales decline of 0.12% year-on-year to $4.94 billion, missing the analyst consensus estimate of $4.98 billion. Organic sales increased by 4.3%. Total Oral, Personal, and Home Care net sales decreased by 0.8% to $3.80 billion. Adjusted EPS of 91 cents beat the consensus estimate of 89 cents.
"This was our sixth consecutive year with organic sales growth at or above our 3% to 5% targeted range. The combination of strong sales growth and operating leverage drove strong bottom-line performance as well, with net income and earnings per share both increasing double digits versus 2023," said Chairman, President, and CEO Noel Wallace.
Colgate said it expects FY25 net sales to be roughly flat, including a mid-single-digit negative impact from foreign exchange.
The company expects organic sales growth to be within its long-term targeted range of 3% to 5%, including the impact of the planned exit from private label pet nutrition in 2025.
Colgate-Palmolive shares fell 0.2% to trade at $86.57 on Monday.
These analysts made changes to their price targets on Colgate-Palmolive following earnings announcement.
<ul>
<li>Morgan Stanley analyst Dara Mohsenian maintained Colgate-Palmolive with an Overweight and lowered the price target from $111 to $104.</li>
<li>Raymond James analyst Olivia Tong reiterated Colgate-Palmolive with an Outperform and lowered the price target from $110 to $105.</li>
<li>RBC Capital analyst Nik Modi maintained the stock with a Sector Perform and lowered the price target from $101 to $98.</li>
<li>Stifel analyst Mark Astrachan maintained Colgate-Palmolive with a Hold and lowered the price target from $95 to $93.</li>
<li>UBS analyst Peter Grom maintained the stock with a Buy and cut the price target from $104 to $100.</li>
</ul>
Considering buying CL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03130429/image-5-1024x524.png" alt="" class="wp-image-763162" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03130429/image-5-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03130429/image-5-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03130429/image-5-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03130429/image-5.png 1143w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Markets

Colgate-Palmolive Analysts Slash Their Forecasts After Q4 Results

UBS analyst Peter Grom maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Buy and lowers the price target from $104 to $100.

Comments

Colgate-Palmolive

Actualités

Dernières nouvelles pour Colgate-Palmolive (NYSE:CL) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL